Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment

MT Newswires Live05-20

Tempus AI (TEM) said Tuesday it is collaborating with Verastem (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.

Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.

The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536489776?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2025-05-20 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536489776","market":"fut","top_or_hot":-1,"title":"Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Tuesday it is collaborating with <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.</p><p>Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.</p><p>The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-20 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Tuesday it is collaborating with <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.</p><p>Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.</p><p>The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4611","symbol_name":"AI医疗","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2536489776","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536489776","pubTimestamp":1747747567,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tempus AI  said Tuesday it is collaborating with Verastem  to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4611":"AI医疗","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4121":"生命科学工具和服务","TEM":"Tempus AI","VSTM":"Verastem","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4139":"生物科技","TEM.AU":"TEMPEST MINERALS LTD","BK4613":"AI应用软件","BK7095":"多种金属与采矿"},"translate_title":"Tempus AI与Verastem合作开发卵巢癌联合治疗诊断测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1,"TEM.AU":1,"VSTM":1},"content_text":"Tempus AI (TEM) said Tuesday it is collaborating with Verastem (VSTM) to develop a companion diagnostic test for a combination treatment for recurrent low-grade serous ovarian cancer.Tempus said it completed confirmatory testing in Verastem's phase 2 clinical trial, which was the basis of the US Food and Drug Administration's recent accelerated approval of the combination of avutometinib and defactinib.The company said its xT companion diagnostic assay is being leveraged as an investigational assay to prospectively evaluate KRAS status in patients with recurrent low-grade serous ovarian cancer and categorize patients into KRAS-mutation or KRAS-wild type groups for analysis in the primary and secondary endpoints of Verastem's global phase 3 clinical trial.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.6","shortVersion":"4.33.6","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536489776"}